Differences in Chemotaxis to Fibronectin in Weakly and Highly Metastatic Tumor Cells

We have examined the chemotactic ability of tumor cell lines with different metastatic potential to plasma fibronectin in Transwell chamber assay. Human renal carcinoma cells with highly metastatic potential, SN12 C‐2, chemotactically migrated to fibronectin (10 μg/ml) about three‐fold more strongly than weakly metastatic SN12 C‐4 cells. Similarly, murine melanoma B16–BL6 cells (highly metastatic) showed higher motility to soluble fibronectin in comparison with weakly metastatic B16–F1 cells. Anti‐VLA‐α3 and β(1), antibodies potently blocked the chemotaxis of both highly and weakly metastatic cells (SN12 C‐2 and C‐4) to fibronectin. This implies that the migration of both C‐2 and C‐4 cells to fibronectin is basically mediated by VLA‐3 receptor. In contrast, the anti‐VLA‐as antibody and RGDS peptide significantly inhibited the chemotaxis of SN12 C‐2 cells to fibronectin, but did not affect weakly metastatic SN12 C‐4 cells. These results suggest that the chemotactic ability to fibronectin positively correlates with the metastatic potential in SN12 and B16 cell lines, and that VLA‐5 receptor is concerned in the motility of highly metastatic SN12 C‐2 cells to soluble fibronectin.